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 Abstract 
 Background: We have previously shown that increased resting-state functional magnetic 
resonance imaging (fMRI)-based functional connectivity (FC) within the frontal resting-state 
networks in Alzheimer’s disease (AD) patients reflects residual, possibly compensatory, func-
tion. This suggests that symptomatic treatments should aim to enhance FC specifically in 
these networks.  Methods: 18 patients with probable AD underwent brain MRI and neuropsy-
chological assessment at baseline and after 12 weeks of treatment with donepezil. We tested 
if changes in cognitive performance after treatment correlated with changes in FC in resting-
state networks known to be altered in AD.  Results: We found increases in FC in the orbito-
frontal network that correlated with cognitive improvement after treatment. The increased FC 
was greatest in patients who responded most to treatment.  Conclusion: This ‘proof of con-
cept’ study suggests that changes in network-specific FC might be a biomarker of pharmaco-
logical intervention efficacy in AD.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
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 Introduction 
 There is increasing evidence that neurodegenerative disorders including Alzheimer’s 
disease (AD) reflect dysfunction of large-scale functional brain networks that can be studied 
with resting-state functional magnetic resonance imaging (rfMRI)  [1] . Functional connec-
tivity (FC) measures correlations of spontaneous fluctuations across brain regions, which can 
be clustered into these large-scale resting-state networks (RSNs) using recently developed 
independent component analysis (ICA) techniques. Several RSNs have been identified with 
these methods  [2] and associated with specific cognitive functions  [3] . It is anticipated that 
relatively simple measures of FC obtained with rfMRI, which does not suffer the complication 
of task-based fMRI, may serve in the future in clinical trials for testing the therapeutic effect 
of new treatments.
 Recent ICA-based rfMRI studies including our own  [4] showed that, among other RSNs, 
the default mode network (DMN), specifically engaged during self-reflection or when subjects 
are at rest, is disrupted in AD patients relative to healthy controls. Conversely, frontal and 
frontoparietal RSNs, which include brain regions associated with working memory and exec-
utive control, are enhanced in AD patients  [5, 6] . By combining resting and task-related fMRI, 
we previously demonstrated that such increased FC in frontal RSNs in AD patients overlaps 
with task-specific hyperactivation that patients exhibit during successful performance of a 
memory task  [4] . Based on this correspondence with task-specific fMRI, we argued that 
increased FC identified using rfMRI in these frontal networks reflects residual, possibly 
compensatory, cognitive ability in AD.
 Our study raised an important issue: should an effective treatment decrease FC in patients 
or increase it in order to reflect a more efficient use of the remaining resources  [5] ? Based on 
our results, we argued that FC in frontal networks would be expected to increase in response 
to treatments aimed to enhance residual ability in AD patients  [4] . Interestingly, cholines-
terase inhibitor therapy, the only currently approved symptomatic treatment for mild-to-
moderate AD, has been shown to improve cognitive performance by upregulating frontal 
systems activation in previous task-based fMRI studies  [7, 8] . However, the effect of treatment 
on ICA-based frontal networks reflecting residual cognitive ability in patients with AD has not 
been explored  [9, 10] .
 In the present ‘proof of concept’ study, we aimed to test the effect of cholinesterase 
inhibitor therapy on the directionality of longitudinal changes in FC in these networks. We 
collected cognitive and multimodal MRI data from patients with AD at baseline (T0) and after 
12 weeks of treatment with donepezil (T1). We then tested whether changes in cognition 
measured with the Montreal Cognitive Assessment (MoCA) correlated with longitudinal 
changes (increases or decreases) in FC. Based on our previous results, we hypothesized that 
cognitive improvement on cholinesterase inhibitor therapy would reflect increased FC specif-
ically within frontal lobe RSNs previously shown to capture residual abilities in AD patients.
 Materials and Methods 
 Participants 
 Eighteen patients (mean age 73.2 ± 6.8 years, female/male = 8/10) with a clinical diag-
nosis of probable AD  [11] were recruited from the Oxford Project to Investigate Memory and 
Ageing (OPTIMA) and from the Oxford Memory Assessment Clinic at the John Radcliffe 
Hospital. Patients had never taken cholinesterase inhibitors. They were asked to participate 
with a carer or informant who knew them well enough to give information about their func-
tioning and cognition. Diagnoses were given by an expert group that included a neurologist, 
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a neuropsychologist, and 2 research nurses with expertise in dementia. Exclusion criteria 
were evidence or history of stroke, epilepsy, focal brain lesions, Parkinson’s disease, fronto-
temporal, vascular or atypical dementia, or any major psychiatric disorder including major 
depression. They also included history of alcohol or substance abuse, contraindication to MRI, 
and active participation in a clinical drug trial. Participants suffering from hypercholester-
olemia, diabetes, and hypertension were included in the study if they had been on stable 
medication for at least a year before the study enrolment. Details about these comorbidities 
and other risk factors are reported in  table 1 . Patients had not smoked, drunken alcohol, or 
taken caffeinated drinks for 24 h before the evaluations.
 Patients underwent medical and neurological examination, neuropsychological as -
sessment, and MRI scan at baseline (T0) and after 12 weeks (T1) of treatment with donepezil 
(5 mg daily for the first 4 weeks, then 10 mg daily). The prescription of cholinesterase inhib-
itors was independently given by the physician attending the memory clinic on the basis of 
clinical need and according to the NICE recommendation. The study was conducted under 
ethical approval from the Central Office for NHS Research Ethics Committees and the Bristol 
Frenchay Research Ethics Committee. All subjects gave written informed consent in accor-
dance with the Declaration of Helsinki.
 The neuropsychological assessment included: Mini-Mental State Examination (MMSE) 
 [12] , MoCA  [13] , Clinical Dementia Rating (CDR) Scale  [14] , Hopkins Verbal Learning Test-
Revised, backwards digits, category and letter fluency  [15] , and Geriatric Depression Scale. A 
semi-structured interview with the carer was carried out to gain information on the patient’s 
cognitive status and included the CDR (informant part), Bristol Activities of Daily Living Scale 
Plus, and Neuropsychiatric Inventory with Caregiver Distress Scale  [16] . Details about demo-
graphic, clinical, neuropsychological and anatomical characteristics are reported in  table 1 .
 Differences (Δ) in the MoCA score were calculated (Δ = T1 – T0) and used for correlation 
with rfMRI. The MoCA was specifically chosen as it is thought to be particularly sensitive to 
subtle cognitive changes by targeting frontal-executive functions in addition to memory and 
other cognitive domains  [13, 17] .
 In addition, participants were classified according to their response to treatment as 
‘responders’ (n = 10, mean age 75.3 ± 4.2 years, mean MMSE T0 = 21.7 ± 3.6) or ‘nonresponders’ 
(n = 8, mean age 70.5 ± 8.6 years, mean MMSE T0 = 20.7 ± 6.3) (see  table 1 for further details). 
They were considered ‘responders’ if an improvement was reported by the carer and demon-
strated by at least two out of three tests of global cognition among MMSE (Δ > 0), MoCA (Δ > 
0), and CDR (Δ < 0).
 MRI Data Acquisition 
 Scanning was performed at the Oxford Centre for Clinical Magnetic Resonance Research 
using a 3T Trio Siemens MRI scanner equipped with a 12-channel head coil. The neuroim-
aging protocol included: (1) rfMRI (EPI T2 * -weighted images; TR/TE = 2,000/28 ms; reso-
lution = 3 × 3 × 3.5 mm 3 ; FOV = 192 mm; number of volumes = 180); (2) diffusion-weighted 
MRI (EPI T2 * -weighted images; TR/TE = 3,000/28 ms; resolution = 3 × 3 × 3 mm 3 ; flip angle 
89°; FOV = 224 mm; number of diffusion directions = 12; b-value = 1,000), and (3) high-reso-
lution T1-weighted 3D MP-RAGE images (TR/TE = 2,040/4.7 ms; resolution = 1 × 1 × 1 mm 3 ; 
FOV 192 mm). Baseline MRI data are also included in a previously published cross-sectional 
comparison with controls and patients with mild cognitive impairment  [4] .
 Structural MRI Analyses 
 Prior to the rfMRI analyses, we tested on T1- and diffusion-weighted MRI data if signif-
icant structural changes had occurred in the 12-week interval to rule out that differences in 
FC were driven by longitudinal changes in gray and/or white matter. T1-weighted images 
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were analyzed with FSL-VBM, an optimized voxel-based morphometry (VBM) protocol  [18, 
19] , to evaluate longitudinal changes in gray matter volume. Diffusion-weighted images were 
corrected for head motion and eddy currents, then FA images were created by fitting a tensor 
model to the raw diffusion data using FDT, and they were brain-extracted using BET. Voxel-
wise statistical analysis of the FA data was carried out using Tract-Based Spatial Statistics 
(TBSS)  [20] to evaluate longitudinal changes in white matter integrity.
 rfMRI Analysis 
 rfMRI data preprocessing with FSL  [21] included brain extraction, head motion correction, 
unwarping using field maps, spatial smoothing (FWHM 6 mm), high-pass filtering (150 s), 
physiological denoising using physiological noise modelling  [22, 23] , and registration of EPI 
images to high-resolution T1 with boundary-based registration  [24] and to MNI space using 
linear and nonlinear registration. Dual regression  [25] was used to derive subject-specific 
versions of the 25 RSN maps from our previous study  [4] . Briefly, in the first step of dual 
regression, the template including the 25 components maps was used in a general linear 
model fit (as spatial regressors) against the fMRI preprocessed data, the output being the 
corresponding temporal dynamics for each component and subject. Secondly, these time 
courses were used in a second general linear model (as temporal regressors) against the fMRI 
data to estimate subject-specific spatial maps. As a result, the values in these maps (parameter 
estimates, PE) represent the connectivity of each voxel with the main regions of the specific 
 Fig. 1. RSNs of interest. The DMN, OFN and left and right frontoparietal networks (FPN) were the focus of 
the current study, as they were previously found to be significantly altered in AD patients relative to controls 
 [4] . Images are shown in radiological convention and MNI coordinates are reported. 
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RSN. For subsequent statistical analyses, we focused on the 4 RSNs that we had previously 
found to be significantly altered in AD patients relative to controls [DMN, orbitofrontal 
network (OFN), left and right frontoparietal RSNs;  fig. 1 ].
 First, we performed paired t tests on these 4 RSNs to obtain longitudinal FC changes 
between T0 and T1 (ΔFC). Because we did not have a placebo control group (it would have 
been unethical to deprive patients from a treatment already approved for AD), we reasoned 
that a change in FC could plausibly be interpreted as an effect of treatment only if it correlated 
with a positive change (Δ > 0) in cognitive scores. Therefore, we performed correlational 
analyses to test whether ΔFC correlated with ΔMoCA. Results were considered significant
for p < 0.05, cluster-corrected for multiple comparisons after initial cluster thresholding at 
p uncorr < 0.05.
 Secondly, for those networks showing a significant correlation with cognitive 
improvement, we performed two explicatory analyses: (a) a paired t test to explore the 
general pattern of longitudinal changes between T0 and T1 (without restricting to regions of 
significant correlation with cognitive scores); (b) a time-by-group analysis comparing 
responders and nonresponders at the two time points to test if one group contributed more 
than the other to FC changes (p < 0.05, cluster-corrected for multiple comparisons after initial 
cluster thresholding at p uncorr < 0.05).
 Results 
 Paired t test analyses showed no significant differences in neuropsychological and 
anatomical characteristics between baseline (T0) and after 12 weeks of treatment (T1). There 
were no significant differences between responders and nonresponders in demographic, 
 Fig. 2. Areas showing significant 
positive correlation between 
changes in MoCA score and chang-
es in FC (red-yellow) and those 
showing a significant FC increase 
after treatment (paired t test, 
blue-light blue) with the orbito-
frontal RSN. Images are shown in 
radiological convention and MNI 
coordinates are reported.  
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clinical, neuropsychological and anatomical characteristics at baseline. We observed no 
differences in these metrics at T1, except the expected significant difference in ΔMMSE 
(responders: 1.5 ± 1.5; nonresponders –1.7 ± 3.4; p = 0.004) and ΔMoCA (responders: 1.8 ± 
2.6; nonresponders –1.3 ± 1.1; p = 0.01).
 No significant structural changes between T0 and T1 were observed with VBM  [18] (p < 
0.05, cluster-corrected for multiple comparisons after initial cluster thresholding at p uncorr < 
0.05) and TBSS  [20] (p < 0.05, corrected for multiple comparisons with threshold-free cluster 
enhancement) analyses, ruling out that any changes in FC are driven by significant longitu-
dinal structural change.
 Analysis of rfMRI data showed that the OFN was the only network showing significant 
results in both correlational and paired t test analyses (p corr < 0.05). There was a significant 
positive correlation between increased FC within the OFN and increased MoCA scores in the 
medial prefrontal cortex  within the anterior cingulate gyrus, precuneus/posterior cingulate 
gyrus, and right dorsolateral frontal regions ( fig. 2 a, c, red-yellow). Direct comparison of FC 
between T0 and T1 in the OFN performed with paired t test explicatory analysis ( fig. 2 b, c, blue-
light blue) also showed increased FC in the precuneus/posterior cingulate gyrus and right 
dorsolateral frontal regions, in addition to subcortical regions in close proximity with the basal 
forebrain cholinergic system (sublenticular forebrain, anterior insula, and caudate). No signif-
icant FC decreases were observed. By repeating the analyses adding voxel-based measures of 
gray matter, the results did not change in localization but were less significant (p uncorr < 0.01).
 Within the areas showing a significantly increased FC after treatment ( fig. 2 b, blue-light 
blue), we extracted the mean PE from the subject-specific spatial maps. The PE values, shown 
in  figure 3 for each subject at T0 and T1, represent the average connectivity of those areas 
with the main regions of the network. The subjects are classified as responders (red) and 
nonresponders (black), showing a greater increase in FC for the responders (although not 
statistically significant). 
 The voxel-wise explicatory time-by-group analysis comparing responders and nonre-
sponders revealed a time-by-group interaction (increased FC higher in responders relative 
to nonresponders) significant at the trend level (p corr = 0.053). This interaction was driven by 
T0 T1
0
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10
15
20
Assessment time point
PE
 (A
U
)
Longitudinal FC changes (OFN)
Nonresponders
Responders
 Fig. 3. PEs extracted from the re-
gions showing a significantly in-
creased FC after treatment in the 
subjects for which the MoCA score 
was available (17 subjects), clas-
sified in responders (red, solid 
lines) and nonresponders (black, 
dashed lines). 
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a significant increase (p corr < 0.05) in FC within the responders group between T0 and T1 
( fig. 4 ) in medial and lateral parietal regions including the precuneus, bilateral dorsal and 
orbitofrontal regions, and right anterior insula and putamen. There were no significant longi-
tudinal changes in the nonresponders group. FC in the OFN was not statistically different at 
baseline between responders and nonresponders but only at T1.
 Discussion 
 We aimed to test the effect of currently approved treatment for AD on the directionality 
of FC changes measured with ICA-based rfMRI. Cross-sectional studies have shown that FC 
within frontal RSNs is increased in patients with AD relative to controls  [5, 6] . Here we present 
a longitudinal pilot study on patients treated with cholinesterase inhibitor therapy (done-
pezil). We found that cognitive improvement following 12 weeks of treatment positively 
correlated with the magnitude of longitudinal increases of FC only within the OFN. This 
suggests that treatment enhances residual function subsided by frontal networks.
 The areas of significant correlation between ΔFC within the OFN and ΔMoCA scores were 
localized in the medial cortex (anterior cingulate gyrus and precuneus/posterior cingulate 
gyrus) and dorsolateral frontal cortex. These areas all receive cholinergic projections from the 
basal forebrain cholinergic system  [9, 26] and have previously been shown to correlate volu-
metrically with the basal forebrain cholinergic system in patients  [27] . Li et al.  [9] also observed 
a significant increase in regional cerebral blood flow and FC in the neural substrates of the 
medial cholinergic pathway (middle and posterior cingulate cortex) in mild AD subjects after 
donepezil treatment, and the changes were correlated with changes in cognitive performance.
 These results indicate a network-specific rather than global, nonspecific effect of done-
pezil on FC. Interestingly, among the RSNs of interest, the OFN is the only one that included 
the basal forebrain cholinergic system  [28] , suggesting that the OFN is specifically sensitive 
to cholinergic-enhancing treatment. This finding of specific modulation of frontal lobe regions 
is consistent with previous PET and fMRI studies  [29] . Increased glucose metabolism was 
observed with FDG PET in patients who responded to treatment with cholinesterase inhib-
itors  [30, 31] . In particular, Potkin et al.  [30] found a marked metabolic increase in the 
prefrontal system, predominantly on the right side, which is in line with the pattern found in 
our study. In fact, although the clusters surviving cluster correction for multiple comparisons 
are clearly right-sided, the uncorrected maps also included most of the corresponding areas 
in the left hemisphere. Task-based fMRI studies on cholinesterase inhibitors showed increased 
brain activation during working memory tasks  [29] , although these results may have been 
biased by the selection of specific fMRI tasks to activate particular brain regions. Instead, our 
results show an effect of donepezil that is task-independent and network-specific.
 Fig. 4. Results of time-by-group 
explicatory analysis. Comparison 
between T0 and T1 within the re-
sponders group: areas showing a 
significant FC increase with the 
OFN are shown in red. Images are 
shown in radiological convention 
and MNI coordinates are reported. 
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 The paired t test analysis performed to directly compare baseline (T0) and 12-week post-
treatment (T1) showed a significant increase in FC within the OFN in the precuneus and right 
dorsolateral frontal regions (also emerged from the correlational analyses), but also in 
subcortical regions including anterior insula, putamen and caudate. This confirms our 
hypothesis that increased FC, observed previously in frontal networks in AD  [5, 6] , is further 
enhanced by cholinergic treatment. The overlap of the results of the paired t test analysis with 
the results of the correlational analysis suggests that the increase in FC is an effect of treatment, 
not a nonspecific effect of disease progression, which, on the contrary, has been shown to be 
associated with decreases in FC over time in a previous ICA-based rfMRI study on the natural 
history of AD  [6] . Thus, the increase in FC that we detected most likely represents an effect of 
the treatment, which affected cortical and subcortical areas of the cholinergic system. Inter-
estingly, it was the increased FC of the more cortical areas (medial and dorsofrontal) that 
directly correlated with cognitive improvement, as no subcortical regions resulted from the 
correlational analysis. The results of the time-by-group analysis, although underpowered for 
the small number of subjects, further showed that the correlation was driven by increased FC 
in responders rather than decreases in nonresponders, although there were no significant 
differences in demographic, clinical, neuropsychological and anatomical characteristics 
between the two groups ( table 1 ). Careful inspection of the outliers revealed that the nonre-
sponder patient with the highest FC increase was one of the youngest subjects (63 years old) 
and had the lowest MMSE (10 both at T0 and at T1), and that the responder with the least FC 
increase had borderline cognitive features suggesting a possible diagnosis of posterior 
cortical atrophy. This suggests that different clinical phenotypes have different effects of FC 
and should be further investigated, and possibly controlled for, in future larger studies. Future 
studies should also investigate if differences between responders and nonresponders are 
specifically driven by pharmacokinetic features such as differences in CYP2D6 status  [32] .
 One limitation of this study is the small sample size. However, this was a ‘proof of concept’, 
whose results encourage further research in this direction. Another limitation of this study is 
that the diagnosis was given on clinical basis (according to McKhann et al.  [11] ) and not 
further supported by biomarkers of amyloidosis. We also did not have a placebo control 
group of the study, as it would have been unethical to delay a treatment already approved for 
AD, but future studies could, for example, selectively recruit for this category AD patients for 
which this therapy is contraindicated. 
 Conclusion 
 Our pilot study shows that FC increases in the OFN reflect the positive effect of treatment 
with donepezil, and possibly other cholinesterase inhibitors, in AD patients. Although addi-
tional work is needed to validate the use of rfMRI in clinical trials, our results suggest that it 
has the potential to be used as surrogate outcome measure to test the effect of new treat-
ments, and may have the greatest utility in early studies to detect an efficacy signal over rela-
tively short time frames.
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